Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
July 25, 2017 1:51 PM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $67.00 (from $62.00) while maintaining a Outperform rating.
Analyst Do Kim recommends buying on weakness following Biogen comments on Spinraza growth to slow in 2H17.
"We believe Spinraza has... More
Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
July 25, 2017 12:05 PM EDTNeedham & Company analyst Chad Messer is telling clients to buy Ionis Pharmaceuticals (NASDAQ: IONS) on weakness as growth concerns overlook the longer-term opportunity.
Messer notes partner Biogen reported $203M in 2Q SPRINRAZA sales, a dramatic increase from $47M in 1Q... More
